{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Super Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Really Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Maybe Good or Maybe Bad"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Good"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Really Good"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Super Good"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"A hedonic VAS was used to assess taste likability or \"palatability\" of a lenvatinib suspension formulated with water or apple juice. Participants scored each category on a scale from 1-7 ranging from super bad (score = 1) to super good (score = 7). As pre-specified by the sSAP, all participants who received suspension formulation were evaluated for palatability and acceptability of the suspension formulation, and data were summarized in an overall safety analysis set irrespective of tumor type. The palatability score based on the overall acceptability category is presented.","groups":[{"description":"Participants received lenvatinib 14 mg/m\\^2 once daily (QD) orally until progressive disease or unacceptable toxicity.","id":"OG000","title":"All Tumor Types"}],"paramType":"NUMBER","populationDescription":"Per protocol, all participants who received suspension formulation were analyzed. Data were summarized in an overall safety analysis set irrespective of tumor type.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (cycle = 28 days)","title":"Palatability Questionnaire For Lenvatinib Suspension Formulation: Participant Responses by Overall Acceptability Category","type":"SECONDARY","unitOfMeasure":"Participants"}